SAD-S35 for COVID-19
SAD-S35 has been reported as potentially beneficial for
treatment of COVID-19. We have not reviewed these studies.
See all other treatments.
, A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New SARS-CoV-2 Variants of Concern, The Journal of Infectious Diseases, doi:10.1093/infdis/jiad102
Abstract Emerging variants of SARS-CoV-2 possess mutations that prevent antibody therapeutics from maintaining anti-viral binding and neutralizing efficacy. Monoclonal antibodies (mAb) shown to neutralize Wuhan-Hu-1 SARS-CoV-2 (ancestral) strain have reduced potency against newer variants. Plasma derived polyclonal hyperimmune drugs have improved neutralization breadth compared to mAbs, but lower titers against SARS-CoV-2 require higher dosages for treatment. We previously developed a highly diverse, recombinant polyclonal antibody therapeutic anti-SARS-CoV-2 immunoglobulin hyperimmune (rCIG). Compared to plasma-derived standard (NIBSC-20/130) or mAb SAD-S35, rCIG has improved neutralization of SARS-CoV-2 across World Health Organization (WHO) variants; however, its potency was reduced against some variants relative to ancestral, in particular omicron. Omicron-specific antibody sequences were enriched from yeast expressing rCIG-scFv antibodies and exhibited increased binding and neutralization to omicron BA.2 while maintaining binding and neutralization to the ancestral strain. Polyclonal antibody libraries such as rCIG can be utilized to develop antibody therapeutics against present and future SARS-CoV-2 threats.
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.